Sina Haftchenary

home / authors / sina-haftchenary

Articles

28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

Kevin Kalinsky, MD, MS;Erika P. Hamilton, MD;Laura Spring;Peter A. Fasching;Sandra Franco, MD;Richard De Boer;Javier Cortes;Dejan Juric;Aditya Bardia, MD, MPH;Sina Haftchenary;Agnes Lteif;Juan Pablo Zarate;Liyi Cen;Patrick Neven, MD, PhD
April 27th 2023
54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)

54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)

Hope S. Rugo, MD;Joyce O'Shaughnessy, MD;Komal Jhaveri;Sara M. Tolaney, MD, MPH;Fatima Cardoso;Aditya Bardia, MD, MPH;Purnima Pathak;Sina Haftchenary;Peter A. Fasching
April 26th 2023

Latest Updated Articles

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Preparing for CAR-T Therapy: Key Considerations and Timing in Multiple Myeloma Treatment
Published: December 20th 2024 | Updated: December 23rd 2024
Preparing for CAR-T Therapy: Key Considerations and Timing in Multiple Myeloma Treatment
Managing CAR-T Therapy: Side Effect Monitoring and Collaborative Patient Care
Published: December 20th 2024 | Updated: December 23rd 2024
Managing CAR-T Therapy: Side Effect Monitoring and Collaborative Patient Care